OpenLB
Open Library of Bioscience
Advanced Search
Evidence-based complementary and alternative medicine : eCAM
2012;2012 136527.

Chloroform Extract of Rasagenthi Mezhugu, a Siddha Formulation, as an Evidence-Based Complementary and Alternative Medicine for HPV-Positive Cervical Cancers.

Anvarbatcha Riyasdeen, Vaiyapuri S Periasamy, Preethy Paul, Ali A Alshatwi, Mohammad A Akbarsha
Author Information
  1. Anvarbatcha Riyasdeen: Department of Animal Science, Bharathidasan University, Tiruchirappalli 620 024, India.
PMID: 22114617 DOI: 10.1155/2012/136527

Abstract

Rasagenthi Mezhugu (RGM) is a herbomineral formulation in the Siddha system of traditional medicine and is prescribed in the southern parts of India as a remedy for all kinds of cancers. However, scientific evidence for its therapeutic efficacy in cervical cancer is lacking, and it contains heavy metals. To overcome these limitations, RGM was extracted, and the fractions were tested on HPV-positive cervical cancer cells, ME-180 and SiHa. The extracts, free from the toxic heavy metals, affected the viability of both the cells. The chloroform fraction (cRGM) induced DNA damage and apoptosis. Mitochondria-mediated apoptosis was indicated. Though both the cells responded to the treatment, ME-180 was more responsive. Thus, this study brings up scientific evidence for the efficacy of RGM against the HPV-mediated cervical cancer cells and, if the toxic heavy metals are the limitation in its use, cRGM would be a suitable candidate as evidence-based complementary and alternative medicine for HPV-positive cervical cancers.

References

  1. Curr Drug Targets. 2011 Jan;12(1):122-32 [PMID: 20735354]
  2. Cancer Lett. 1991 Mar;56(3):231-4 [PMID: 2021927]
  3. Biol Pharm Bull. 2004 Oct;27(10):1604-10 [PMID: 15467204]
  4. Int J Mol Med. 2005 Jun;15(6):1013-22 [PMID: 15870908]
  5. Cancer. 2006 Aug 1;107(3):459-66 [PMID: 16795065]
  6. J Cell Biol. 1999 Mar 8;144(5):891-901 [PMID: 10085289]
  7. Cancer Chemother Pharmacol. 2004 Jul;54(1):7-15 [PMID: 15042313]
  8. Biol Res Nurs. 2009 Apr;10(4):392-9 [PMID: 19251719]
  9. EMBO J. 1989 Dec 1;8(12):3905-10 [PMID: 2555178]
  10. Arch Pharm Res. 2001 Jun;24(3):211-3 [PMID: 11440079]
  11. Int J Gynaecol Obstet. 2009 Aug;106(2):141-3 [PMID: 19535071]
  12. Cancer Res. 1996 Mar 1;56(5):1023-30 [PMID: 8640756]
  13. Cell Biol Int. 2007 Oct;31(10):1198-206 [PMID: 17572113]
  14. Redox Rep. 2004;9(2):105-10 [PMID: 15231065]
  15. J Ethnopharmacol. 2010 Aug 9;130(3):460-4 [PMID: 20669365]
  16. Mutat Res. 2011 Jan 10;706(1-2):28-35 [PMID: 21040738]
  17. Int J Oncol. 2007 Apr;30(4):813-23 [PMID: 17332919]
  18. Evid Based Complement Alternat Med. 2011;2011:578092 [PMID: 19706693]
  19. Chem Biol Interact. 2009 Sep 14;181(1):77-84 [PMID: 19481070]
  20. Clin Chim Acta. 2004 Apr;342(1-2):203-10 [PMID: 15026282]
  21. Cancer Lett. 2008 Jun 18;264(2):229-40 [PMID: 18343026]
  22. Virus Res. 2002 Nov;89(2):213-28 [PMID: 12445661]
  23. Nutr Cancer. 2003;47(2):171-80 [PMID: 15087270]
  24. J Ethnopharmacol. 2006 Apr 21;105(1-2):154-60 [PMID: 16388923]
  25. J Ethnopharmacol. 1999 Jun;65(3):237-41 [PMID: 10404422]
  26. Fitoterapia. 2004 Jul;75(5):500-4 [PMID: 15261389]
  27. J Ethnopharmacol. 2007 Feb 12;109(3):529-34 [PMID: 17034970]
  28. J Ethnopharmacol. 2005 Feb 28;97(2):231-5 [PMID: 15707758]
  29. Curr Opin Pharmacol. 2001 Aug;1(4):364-9 [PMID: 11710734]
  30. Anticancer Res. 2008 Mar-Apr;28(2A):785-92 [PMID: 18507021]
  31. J Ethnopharmacol. 2002 Aug;81(3):327-36 [PMID: 12127233]
  32. Cancer Lett. 2008 Oct 8;269(2):199-225 [PMID: 18479807]
  33. Toxicol Sci. 2006 May;91(1):59-69 [PMID: 16443926]
  34. Fitoterapia. 2005 Sep;76(6):549-55 [PMID: 16009505]
  35. Phytother Res. 2011 Aug;25(8):1209-14 [PMID: 21308820]
  36. J Agric Food Chem. 2004 Feb 25;52(4):912-5 [PMID: 14969550]
  37. J Med Food. 2010 Apr;13(2):371-81 [PMID: 20210607]
  38. West J Med. 1982 Dec;137(6):531-9 [PMID: 7164433]
  39. J Ethnopharmacol. 2006 May 24;105(3):336-41 [PMID: 16412596]
  40. Evid Based Complement Alternat Med. 2005 Dec;2(4):465-73 [PMID: 16322803]
  41. Mol Pharmacol. 2000 Dec;58(6):1287-93 [PMID: 11093765]
  42. Asian Pac J Cancer Prev. 2007 Oct-Dec;8(4):578-82 [PMID: 18260732]
  43. Int Immunopharmacol. 2003 Jan;3(1):53-61 [PMID: 12538034]
  44. Phytomedicine. 2001 Sep;8(5):401-9 [PMID: 11695885]
  45. Pharmacol Res. 2005 Dec;52(6):467-74 [PMID: 16140022]
  46. Biol Pharm Bull. 2005 Sep;28(9):1639-44 [PMID: 16141531]
  47. Boll Chim Farm. 1998 Dec;137(11):443-7 [PMID: 10077878]
  48. J Ethnopharmacol. 2009 Apr 21;122(3):450-6 [PMID: 19429311]
  49. J Gynecol Oncol. 2009 Jun;20(2):72-6 [PMID: 19590717]
  50. Exp Cell Res. 1988 Mar;175(1):184-91 [PMID: 3345800]
  51. J Ethnobiol Ethnomed. 2006 Oct 07;2:43 [PMID: 17026769]
  52. J Ethnopharmacol. 2006 Jun 30;106(2):179-86 [PMID: 16442763]
  53. J Ethnopharmacol. 2004 Feb;90(2-3):339-46 [PMID: 15013199]
  54. Mol Carcinog. 2007 Mar;46(3):231-41 [PMID: 17186548]
  55. Mol Cancer Ther. 2003 Jun;2(6):573-80 [PMID: 12813137]
  56. Anticancer Res. 2005 May-Jun;25(3B):2199-204 [PMID: 16158964]
  57. Chem Biol Interact. 2008 Feb 15;171(3):272-82 [PMID: 18076871]
  58. Mol Cell Biochem. 2005 Dec;280(1-2):125-33 [PMID: 16311913]
  59. Pharmacol Res. 2005 Jan;51(1):19-30 [PMID: 15519531]
Journal Article
Article has an altmetric score of 6

Word Cloud

Created with Highcharts 10.0.0cervicalcellsRGMcancerheavymetalsRasagenthiMezhuguSiddhamedicinecancersscientificevidenceefficacyHPV-positiveME-180toxiccRGMapoptosisherbomineralformulationsystemtraditionalprescribedsouthernpartsIndiaremedykindsHowevertherapeuticlackingcontainsovercomelimitationsextractedfractionstestedSiHaextractsfreeaffectedviabilitychloroformfractioninducedDNAdamageMitochondria-mediatedindicatedThoughrespondedtreatmentresponsiveThusstudybringsHPV-mediatedlimitationusesuitablecandidateevidence-basedcomplementaryalternativeChloroformExtractFormulationEvidence-BasedComplementaryAlternativeMedicineHPV-PositiveCervicalCancers

Similar Articles

Cited By